Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

NCT05222438 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No accrual of participants in 18 months

Conditions

Relapsed Diffuse Large B-cell Lymphoma

Interventions

DRUG: loncastuximab tesirine

Sponsor

Barbara Ann Karmanos Cancer Institute